Alcidion has raised capital
October 2023 — Alcidion Group Ltd. (ASX:ALC) has raised capital via an institutional placement. The placement was well supported by existing shareholders whilst also welcoming several new institutional shareholders to the register. Proceeds from the raise will provide Alcidion with maximum flexibility and ensure a strong balance sheet to execute on its market opportunities and enable the firm to continue to drive revenue growth.
Alcidion is a market leading healthcare software informatics company providing an innovative technology platform to improve the efficiency and quality of patient care. Its flagship platform, Miya Precision, can be deployed in a modular approach to accommodate varying customer priorities and budget profiles across the UK, Australia and New Zealand markets.
At the end of September 2023, Alcidion had A$35.3 million (US$23m) of contracted revenue for FY24 (expected to grow over the remainder of the year) and is forecasting to be EBITDA and cashflow positive.
Our role in the transaction
Oaklins’ team in Australia acted as lead manager in this transaction.
Contacter l'équipe de la transaction
Justin Lewis
Oaklins Henslow
Transactions connexes
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
En apprendre plusVeremark has completed a secondary share sale
Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.
En apprendre plusKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
En apprendre plus